Key result
Persistently elevated C-reactive protein levels (≥5 mg/L) after percutaneous coronary intervention were significantly associated with an increased incidence of major adverse cardiovascular events compared to levels <5 mg/L (32.3% vs. 7.0%, p<0.001).
Why the study?
Inflammation plays a key role in complications after PCI, but the clinical and prognostic significance of CRP dynamics post-PCI remains to be clarified.
Does persistently elevated CRP after percutaneous coronary intervention predict an increased risk of in-stent restenosis, stent thrombosis, and MACE in patients with ischemic heart disease?
Cohort (n=102)
No
Does persistently elevated CRP after percutaneous coronary intervention predict an increased risk of in-stent restenosis, stent thrombosis, and MACE in patients with ischemic heart disease?
Absolute Event Rate: 32.3% vs 7%
p-value: p=<0.001
Dynamic monitoring of CRP after PCI offers important prognostic value, as persistently elevated levels (≥5 mg/L) strongly predict increased risks of in-stent restenosis, stent thrombosis, and MACE.
The aim of this study was to evaluate the dynamics of C-reactive protein (CRP) levels in patients with ischemic heart disease following percutaneous coronary intervention (PCI) and to determine its prognostic value for in-stent restenosis, stent thrombosis, and major adverse cardiovascular events (MACE). A total of 102 patients who underwent PCI were prospectively enrolled in the study. CRP levels were measured before the procedure and at 24 hours, 1 month, 3 months, 6 months, and 9 months after the intervention. During the follow-up period, the incidence of in-stent restenosis, stent thrombosis, and MACE was evaluated. The results demonstrated that CRP reached its peak within the first 24 hours after PCI and subsequently showed a gradual decline throughout the follow-up period. Persistently elevated CRP levels were significantly associated with an increased risk of in-stent restenosis, stent thrombosis, and MACE (p<0.05). These findings indicate that CRP is an important prognostic biomarker in patients after PCI. Dynamic monitoring of CRP may facilitate early identification of high-risk patients, support individualized clinical follow-up, and improve the prediction of adverse cardiovascular outcomes.
No takes yet. Share an insight, caveat, or question.
J. Kh. Tursunov (2026) conducted a cohort in Ischemic heart disease (n=102). Persistently elevated C-reactive protein (≥5 mg/L) vs. C-reactive protein <5 mg/L was evaluated on Major adverse cardiovascular events (MACE) at 9 months (p=<0.001). Persistently elevated C-reactive protein levels (≥5 mg/L) after percutaneous coronary intervention were significantly associated with an increased incidence of major adverse cardiovascular events compared to levels <5 mg/L (32.3% vs. 7.0%, p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: